Author: Dev

CanCell Therapeutics partners with Ovizio to improve monitoring of CAR-T cell production

CanCell Therapeutics partners with Ovizio to improve monitoring of CAR-T cell production

Ovizio Imaging Systems, a manufacturer of cell analyzers for advanced monitoring in the bioprocessing market, and CanCell Therapeutics, an early-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that they will enter into a collaboration to further improve the monitoring of CAR-T cell-therapy manufacturing. The partnership

Read More
Zeotap launches Predictive Audiences to empower marketers with machine learning

Zeotap launches Predictive Audiences to empower marketers with machine learning

Zeotap the leading Customer Data Platform, has today announced the launch of Predictive Audiences as part of its award-winning Customer Intelligence Platform (CIP). Designed to help marketing users increase the impact of their campaigns, it enables the creation and application of machine-learned predictive segments in just a few clicks. Predictive

Read More
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial

Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial

Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal

Read More
Zeotap builds momentum as marketing industry shifts away from cookies

Zeotap builds momentum as marketing industry shifts away from cookies

Zeotap, the Customer Intelligence Platform (CIP), has reported 126% ARR growth in 2020 among its latest milestones in growth. Building momentum from its $60.5 million Series C fundraising round last year, the company is capitalizing on the marketing industry’s move to better engage first-party data in the face of the

Read More
Ventyx Biosciences doses first subject in a Phase 1 Trial of VTX-958, a selective allosteric TYK2 Inhibitor for Autoimmune Diseases

Ventyx Biosciences doses first subject in a Phase 1 Trial of VTX-958, a selective allosteric TYK2 Inhibitor for Autoimmune Diseases

Ventyx Biosciences, Inc. a clinical-stage biotechnology company developing oral, small molecule therapeutics for autoimmune disease, today announced the dosing of the first subject in a Phase 1 clinical trial of VTX-958, a novel and selective allosteric TYK2 inhibitor.  In non-clinical studies, VTX-958 has shown potential to treat autoimmune diseases by

Read More
TigerConnect acquires Critical Alert

TigerConnect acquires Critical Alert

TigerConnect®, healthcare’s most advanced, reliable, and widely adopted care team collaboration solution, today announced the acquisition of Critical Alert®, a leading provider of enterprise-grade middleware for hospitals and health systems. Critical Alert’s product suite consists of a middleware suite of products as well as traditional nurse call hardware servicing over

Read More
Amarisoft and Dali Wireless Collaborate to Deliver Open RAN Based 4G and 5G Solutions

Amarisoft and Dali Wireless Collaborate to Deliver Open RAN Based 4G and 5G Solutions

Interoperability and co-marketing initiatives will bring new options for enterprises, and mobile network operators deploying in-building cellular solutions Menlo Park, California and Paris, France – February 11, 2020 – Dali Wireless, a global leader in wireless fronthaul innovation for virtual RAN, and Amarisoft, a pioneer in software centric 4G LTE

Read More
ProterixBio licenses COVID-19 serology test from Massachusetts General Hospital

ProterixBio licenses COVID-19 serology test from Massachusetts General Hospital

Billerica, MA, July 1, 2020: ProterixBio, Inc. today announced completing a licensing agreement with the Massachusetts General Hospital for a COVID-19 serology assay. The assay was developed and validated by researchers at the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University which is a joint

Read More
Perceptimed Awarded NIH Development Grant

Perceptimed Awarded NIH Development Grant

PERCEPTIMED AWARDED $1.5M NIH DEVELOPMENT GRANT   MOUNTAIN VIEW, CA – PerceptiMed, Inc., was awarded a $1.5 million grant from the National Institutes of Health (NIH) to develop and test a secure, individual medication system for long-term care facilities.  Dr. Alan Jacobs, CEO and founder of PerceptiMed will serve as

Read More
Perceptimed Founder Jacobs To Speak At Bio2device Group Event

Perceptimed Founder Jacobs To Speak At Bio2device Group Event

PERCEPTIMED FOUNDER JACOBS TO SPEAK AT BIO2DEVICE GROUP EVENT MOUNTAIN VIEW, CA – April 25, 2014 – “Preventing Drug-Related Patient Injury and Death with Advanced, Cost-Effective Technology” is the topic Alan Jacobs, M.D., Ph.D., CEO and founder of PerceptiMed, will address at the Bio2Device lecture.  The lecture will take place

Read More
2019: A Look Back

2019: A Look Back

2019 was an exciting and busy year for us! As we take a look back at some of our milestones, we’d like to give a big thank you to all of our publishers. We’re looking forward to what’s in store in the coming year! We’re happy to report that 2019

Read More
For Digital Publishers, GTxcel’s New Content Hub is a Potential Game Changer

For Digital Publishers, GTxcel’s New Content Hub is a Potential Game Changer

Faced with a growing ecosystem of platforms and distribution channels, digital publishers rely on more sophisticated tools to effectively deliver content and maintain their brand cohesiveness. If you’re like most digital publishers, you probably maintain a network of content distribution channels. Your digital edition, branded website, blog, video channel, and

Read More